{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:45:20Z","timestamp":1788878720895,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2705003"],"award-info":[{"award-number":["2022YFC2705003"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515110546"],"award-info":[{"award-number":["2020A1515110546"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170176"],"award-info":[{"award-number":["82170176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970194"],"award-info":[{"award-number":["81970194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.canlet.2024.216797","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T04:19:39Z","timestamp":1709871579000},"page":"216797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Induction of IFIT1\/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis"],"prefix":"10.1016","volume":"588","author":[{"given":"Yuanming","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoli","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingpei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueya","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuening","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-3812","authenticated-orcid":false,"given":"Xinliang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.canlet.2024.216797_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","article-title":"Pyroptosis: gasdermin-mediated programmed necrotic cell death","volume":"42","author":"Shi","year":"2017","journal-title":"Trends Biochem. Sci."},{"issue":"9","key":"10.1016\/j.canlet.2024.216797_bib2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.tcb.2017.05.005","article-title":"Gasdermins: effectors of pyroptosis","volume":"27","author":"Kovacs","year":"2017","journal-title":"Trends Cell Biol."},{"issue":"9","key":"10.1016\/j.canlet.2024.216797_bib3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.tcb.2023.02.007","article-title":"Gasdermins gone wild: new roles for GSDMs in regulating cellular homeostasis","volume":"33","author":"Weindel","year":"2023","journal-title":"Trends Cell Biol"},{"issue":"3","key":"10.1016\/j.canlet.2024.216797_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2023.194955","article-title":"Ubiquitination is a major modulator for the activation of inflammasomes and pyroptosis","volume":"1866","author":"Jiang","year":"2023","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"issue":"7661","key":"10.1016\/j.canlet.2024.216797_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","article-title":"Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin","volume":"547","author":"Wang","year":"2017","journal-title":"Nature"},{"issue":"43","key":"10.1016\/j.canlet.2024.216797_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"issue":"8","key":"10.1016\/j.canlet.2024.216797_bib7","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41591-018-0082-y","article-title":"DPP8\/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia","volume":"24","author":"Johnson","year":"2018","journal-title":"Nat. Med."},{"issue":"10272","key":"10.1016\/j.canlet.2024.216797_bib8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.canlet.2024.216797_bib9","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41401-023-01060-3","article-title":"Proteasomal inhibitors induce myeloma cell pyroptosis via the BAX\/GSDME pathway","volume":"44","author":"Liang","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2024.216797_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156376","article-title":"Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer","volume":"171","author":"Bhat","year":"2023","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.canlet.2024.216797_bib11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0268-960X(97)90019-9","article-title":"Role of alpha interferon in multiple myeloma","volume":"11","author":"Joshua","year":"1997","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.canlet.2024.216797_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41419-023-05728-w","article-title":"Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients","volume":"14","author":"Holicek","year":"2023","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.canlet.2024.216797_bib13","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood.2020005199","article-title":"Targeting the Otub1\/c-Maf axis for the treatment of multiple myeloma","volume":"137","author":"Xu","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.canlet.2024.216797_bib14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2008-02-142687","article-title":"Cyproheptadine displays preclinical activity in myeloma and leukemia","volume":"112","author":"Mao","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.canlet.2024.216797_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/ejh.12176","article-title":"Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate","volume":"91","author":"Holien","year":"2013","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.canlet.2024.216797_bib16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/CAD.0000000000000466","article-title":"Nitroxoline shows antimyeloma activity by targeting the TRIM25\/p53 axle","volume":"28","author":"Mao","year":"2017","journal-title":"Anti Cancer Drugs"},{"issue":"5","key":"10.1016\/j.canlet.2024.216797_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.188","article-title":"MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT\/mTOR pathway","volume":"8","author":"Xiang","year":"2017","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.canlet.2024.216797_bib18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2024.216797_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12964-020-00676-w","article-title":"Inhibition of the Otub1\/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis","volume":"19","author":"Sun","year":"2021","journal-title":"Cell Commun. Signal."},{"issue":"12","key":"10.1016\/j.canlet.2024.216797_bib20","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/s41401-019-0249-1","article-title":"Mebendazole elicits potent antimyeloma activity by inhibiting the USP5\/c-Maf axis","volume":"40","author":"Chen","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.canlet.2024.216797_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41420-022-00915-8","article-title":"GSDMD enhances cisplatin-induced apoptosis by promoting the phosphorylation of eIF2alpha and activating the ER-stress response","volume":"8","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.canlet.2024.216797_bib22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/leu.2008.232","article-title":"Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma","volume":"23","author":"Mao","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.canlet.2024.216797_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.chembiol.2017.03.009","article-title":"Pyroptosis and apoptosis pathways engage in bidirectional crosstalk in monocytes and macrophages","volume":"24","author":"Taabazuing","year":"2017","journal-title":"Cell Chem. Biol."},{"issue":"43","key":"10.1016\/j.canlet.2024.216797_bib24","doi-asserted-by":"crossref","first-page":"70143","DOI":"10.18632\/oncotarget.12160","article-title":"Interferon-stimulated gene 15 induces cancer cell death by suppressing the NF-kappaB signaling pathway","volume":"7","author":"Mao","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.canlet.2024.216797_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2024.216797_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106615","article-title":"Targeting Type I IFN\/STAT1 signaling inhibited and reversed corneal squamous metaplasia in Aire-deficient mouse","volume":"187","author":"Yu","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.canlet.2024.216797_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"1\u20133","key":"10.1016\/j.canlet.2024.216797_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2008.08.015","article-title":"The toxicology of Clioquinol","volume":"182","author":"Mao","year":"2008","journal-title":"Toxicol. Lett."},{"issue":"14","key":"10.1016\/j.canlet.2024.216797_bib29","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jnci\/djq198","article-title":"Effect of noncompetitive proteasome inhibition on bortezomib resistance","volume":"102","author":"Li","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2024.216797_bib30","article-title":"Venetoclax and bortezomib in relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia","volume":"3","author":"La Starza","year":"2019","journal-title":"JCO Precis Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2024.216797_bib31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2024.216797_bib32","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-06-3546","article-title":"Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216797_bib33","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1038\/srep05749","article-title":"Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway","volume":"4","author":"Cao","year":"2014","journal-title":"Sci. Rep."},{"issue":"47","key":"10.1016\/j.canlet.2024.216797_bib34","doi-asserted-by":"crossref","first-page":"34181","DOI":"10.1074\/jbc.M113.472563","article-title":"The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity","volume":"288","author":"Cao","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.canlet.2024.216797_bib35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2174\/156800911794519770","article-title":"Clioquinol - a novel copper-dependent and independent proteasome inhibitor","volume":"11","author":"Schimmer","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.canlet.2024.216797_bib36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41580-022-00564-w","article-title":"Pore-forming proteins as drivers of membrane permeabilization in cell death pathways","volume":"24","author":"Vandenabeele","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2024.216797_bib37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41467-022-35348-5","article-title":"Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis","volume":"14","author":"Arimoto","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.canlet.2024.216797_bib38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.immuni.2018.01.014","article-title":"Human IFIT3 modulates IFIT1 RNA binding specificity and protein stability","volume":"48","author":"Johnson","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.canlet.2024.216797_bib39","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-Stimulated genes: what do they all do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu Rev. Virol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:42:29Z","timestamp":1760816549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":39,"alternative-id":["S0304383524001903"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216797","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction of IFIT1\/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216797"}}